Home High-Flow Nasal Cannula vs. Noninvasive Ventilation for Stable Chronic Respiratory Failure

Launched by WONJU SEVERANCE CHRISTIAN HOSPITAL · Mar 10, 2025

Keywords

ClinConnect Summary

This clinical trial is comparing two different types of breathing support for people with stable chronic respiratory failure, specifically those who have high levels of carbon dioxide in their blood. The two therapies being studied are high-flow nasal cannula (HFNC) and noninvasive ventilation (NIV). The main goals are to see which method better lowers carbon dioxide levels, how comfortable patients are with each option, and whether there are differences in overall well-being, such as oxygen levels and quality of life.

To be eligible for the trial, participants need to be adults aged 40 or older with a diagnosis of chronic obstructive pulmonary disease (COPD) and certain blood gas levels. They should also be able to read and write in Korean and provide written consent to join the study. If you participate, you will use either the HFNC or NIV device for at least four hours each night over six weeks, with regular check-ups at the hospital. After six weeks, you will switch to the other device to compare the results. This study is not yet recruiting, so there will be more information available in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult aged 40 years or older
• • Diagnosed with COPD
• • Arterial blood gas test, pCO2 \> 45 mmHg at stable status
• • A person who can read or write in Korean
• • Written informed consent to participate in this study
• Exclusion Criteria:
• • A person who disagrees with the content of a informed consent
• • Those who have difficulty wearing NIV or HFNC
• • Cognitive impairment or apsychiatric disorder
• • Hypoxic or hypercapnic exacerbation within the previous four weeks